Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer
Portfolio Pulse from Vandana Singh
Candel Therapeutics announced new data from an ongoing phase 1 trial of its CAN-3110 viral immunotherapy candidate for high-grade glioma. The treatment was well tolerated and showed encouraging responses in patients. CADL shares are down 7.38% at $1.58.
May 19, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Candel Therapeutics' CAN-3110 shows promising results in phase 1 trial for high-grade glioma, but CADL shares are down 7.38% at $1.58.
The positive results from the phase 1 trial of CAN-3110 indicate potential for the treatment's success in the future. However, the stock price has dropped 7.38%, which may be due to short-term market fluctuations or investor sentiment. The news is highly relevant and important for CADL investors, but the short-term impact on the stock price is negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100